Intercept Pharmaceuticals, Inc. (ICPT): Price and Financial Metrics


Intercept Pharmaceuticals, Inc. (ICPT)

Today's Latest Price: $48.04 USD

0.46 (0.97%)

Updated Aug 5 8:00pm

Add ICPT to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 343 in Biotech

See all "A" rated Strong Buy stocks

ICPT Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for ICPT is -7.85 -- better than only 2.24% of US stocks.
  • ICPT's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 91.61% of US stocks.
  • Revenue growth over the past 12 months for Intercept Pharmaceuticals Inc comes in at 38.91%, a number that bests 87.09% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to ICPT, based on their financial statements, market capitalization, and price volatility, are IRWD, RDUS, BNFT, FLXN, and TTOO.
  • ICPT's SEC filings can be seen here. And to visit Intercept Pharmaceuticals Inc's official web site, go to www.interceptpharma.com.
ICPT Daily Price Range
ICPT 52-Week Price Range

ICPT Stock Price Chart Technical Analysis Charts


ICPT Price/Volume Stats

Current price $48.04 52-week high $125.00
Prev. close $47.58 52-week low $42.19
Day low $47.40 Volume 777,560
Day high $49.20 Avg. volume 764,484
50-day MA $60.49 Dividend yield N/A
200-day MA $82.24 Market Cap 1.58B

Intercept Pharmaceuticals, Inc. (ICPT) Company Bio


Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic underserved liver diseases. The company was founded in 2002 and is based in New York, New York.





ICPT Latest News Stream


Event/Time News Detail
Loading, please wait...

ICPT Latest Social Stream


Loading social stream, please wait...

View Full ICPT Social Stream

Latest ICPT News From Around the Web

Below are the latest news stories about Intercept Pharmaceuticals Inc that investors may wish to consider to help them evaluate ICPT as an investment opportunity.

Intercept Pharmaceuticals (ICPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Intercept (ICPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 29, 2020

Intercept Pharma higher on activist chatter

A rumor making the rounds says a large activist may be getting involved with Intercept Pharma (ICPT) to push for sale.Intercept disappointed in late June when it received a CRL from the FDA for its application for the use of obeticholic acid ((OCA)) to treat liver fibrosis due to nonalcoholic...

Seeking Alpha | July 16, 2020

The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Altimmune Inc (NASDAQ: ALT ) (priced its $115 million worth of common stock and pre-funded warrant offering) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Imv Inc (NASDAQ: IMV ) (provided an update on its coronavirus vaccine program) INmune Bio Inc (NASDAQ: INMB )( announced positive interim Phase 1b data for its Alzheimer's drug) OncoSec Medical Inc (NASDAQ: ONCS ) Qiagen NV (NYSE: QGEN ) Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL ) (announced initiation of clinical study of its fostamatinib for treating COVID-19 pneumonia) TIZIANA LF SCIE/S ADR (NASDAQ: TLSA ) Vaxart Inc (NASDAQ:...

Benzinga | July 15, 2020

The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 9) Affimed NV (NASDAQ: AFMD ) Altimmune Inc (NASDAQ: ALT ) argenx SE – ADR (NASDAQ: ARGX ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Bio-Rad Laboratories, Inc. (NYSE: BIOV ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCMV Dynavax Technologies Corporation (NASDAQ: DVAX ) Eli Lilly And Co (NYSE: LLY ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therapeutics Inc (NASDAQ: NTLA ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Meridian Bioscience, Inc. (NASDAQ: VIVO ) Nantkwest Inc (NASDAQ: NK ) NeoGenomics, Inc. (...

Benzinga | July 10, 2020

Biogen Stock Is Jumping. The Biotech Submitted Its Troubled Alzheimer’s Drug for FDA Approval.

Biogen has finished submitting its application for approval for aducanumab to the Food and Drug Administration. That submission was originally expected to be completed in early 2020.

Yahoo | July 8, 2020

Read More 'ICPT' Stories Here

ICPT Price Returns

1-mo 4.21%
3-mo -43.37%
6-mo -49.52%
1-year -20.80%
3-year -55.16%
5-year -79.68%
YTD -61.23%
2019 22.95%
2018 72.53%
2017 -46.23%
2016 -27.25%
2015 -4.26%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9767 seconds.